The Oncology Institute names Anne McGeorge as new chairman

CERRITOS, Calif. - The Oncology Institute (NASDAQ:TOI) announced Wednesday that Anne McGeorge will succeed Richard Barasch as Chairman of the Board, effective August 12, 2025, following Barasch’s retirement.

McGeorge, who joined TOI’s board in 2021 and currently serves as Chair of the Audit Committee, brings over 35 years of healthcare financial experience to the role. Prior to retiring in 2017, she launched and led Grant Thornton LLP’s Global Health Care and Life Sciences Practice as managing partner for 10 years, growing it into a $250 million global business.

Her career includes partner positions at Deloitte and Arthur Andersen, as well as serving as an adjunct professor at the University of North Carolina School of Public Health. McGeorge currently holds board positions at several healthcare companies, including Dianthus Therapeutics (NASDAQ:DNTH), Nimbus Therapeutics, and CitiusTech.

"I am honored to serve as Chairman and look forward to working with the board and management team to continue advancing our mission of providing exceptional oncology care," McGeorge said in the press release.

Daniel Virnich, CEO of The Oncology Institute, expressed confidence in McGeorge’s appointment, citing her "extensive experience in providing strategic guidance to management teams, deep knowledge of the healthcare space and proven financial acumen."

The Oncology Institute describes itself as one of the largest value-based oncology groups in the United States, with over 180 employed and affiliate clinicians across more than 100 clinics and affiliate locations in five states.

In other recent news, Dianthus Therapeutics has been the focus of several analyst updates ahead of its anticipated clinical trial data release. Guggenheim has increased its price target for the company to $92.00 from $84.00, maintaining a Buy rating as Dianthus prepares to release Phase II MaGic trial data for its DNTH103 treatment in generalized myasthenia gravis in September 2025. Stifel also reiterated its Buy rating and maintained a $52.00 price target, highlighting the upcoming Phase 2 data as the first clinical readout for the company in this autoimmune condition.

William Blair has initiated coverage on Dianthus Therapeutics with an Outperform rating, assigning a fair value of $47.57 per share. This marks the 13th Buy rating for the company, indicating positive sentiment among analysts. The firm has identified Dianthus as a clinical-stage biotechnology company focused on developing DNTH103, an active C1s monoclonal antibody. The company’s management has expressed confidence in their drug candidate, emphasizing its potential to treat autoantibody-driven diseases effectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.